Mundipharma Pharmaceuticals Limited – statement in response to Covid-19
Updated: 18 May 2020
As the world continues to take unprecedented action in response to the Coronavirus pandemic, nobody is left unaffected. At Mundipharma, we have responded at pace to ensure that we protect the health of our employees, partners, suppliers, and contractors, as a priority.
Since the outbreak of the virus, Mundipharma has taken all precautions and steps to ensure our supply chain remains robust and that provision of our medicines to the patients that depend on them continues uninterrupted. To date, there has been no disruption to our supply of medicines.
We have also worked tirelessly to ensure business continuity plans are in place, so that we can continue to deliver on our commitments to healthcare professionals, patient and professional groups, and external partners. This includes the rapid adoption of novel digital solutions across every part of our business, so that we can continue to deliver a high-quality service that meets the needs of healthcare professionals and our customers.
Our employees continue to be fully supported to work flexibly and are home-based wherever possible. For our people with essential roles that require them to be on-site, such as supply and manufacturing, we are actively following all relevant WHO and International guidelines to safeguard them.
We know that the impact of this pandemic will be long-term and far-reaching. As such, we remain unwavering in our support – both internally and externally – during these most difficult of times.
What We Do
We partner with global pharmaceutical companies to license, develop and deliver trusted medications more effectively in the areas of Diabetes, Respiratory and Biosimilars to improve the lives of patients.
About Mundipharma Ireland
Mundipharma Ireland is fast becoming one of Ireland’s most innovative pharmaceutical companies.
We work at a local level but with the backing and support of a global network.
Medicines are only part of the solution to health issues.
Find out more about living with your condition, and how we support you and your community
Our product information and other resources are available to support healthcare professionals working to support patients.
Our biosimilar products offer cost effective treatments for people living with debilitating diseases, such as breast cancer, gastric cancer, rheumatoid arthritis and haematological malignancies.
The Mundipharma global network of
independent associated companies:
Active in more than
120 worldwide markets;
30 in Europe
Together, these businesses
employ more than
European sales exceeding